Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01475955 · ClinicalTrials.gov registry record · Phase 2

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

A Phase 2 study, sponsored by DUSA Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
235
Enrollment target

NCT01475955: Completed Phase 2 study, sponsored by DUSA Pharmaceuticals.

NCT01475955 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 235 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01475955, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
235 participants
Enrollment target

Study Summary

The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.

Primary Outcome

The proportion of subjects in each treatment group with a count of zero lesions in the Treatment Area

Interventions

  • DRUG Broad Area ALA 1-hour incubation
  • DRUG Broad Area ALA 2 hour incubation
  • DRUG broad area ALA 3-hour incubation
  • DRUG Spot ALA 2 hour incubation
  • DRUG Vehicle PDT

Trial Details

FieldValue
Enrollment Target 235 participants
Start Date 2011-12
Est. Completion 2012-11
Phase Phase 2
DUSA Pharmaceuticals

10 total trials

What the finished NCT01475955 record still lists

NCT01475955 is an interventional study that assigns participants to a tested intervention. The registered 235 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% higher).

The record links to 0 conditions, and to 5 interventions - of which Broad Area ALA 1-hour incubation is the first listed.

NCT01475955 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01475955 about?

NCT01475955 is a clinical study titled "Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)". The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.

What is the current status of trial NCT01475955?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2011-12. Estimated completion is 2012-11.

What interventions are being tested in trial NCT01475955?

The interventions under investigation include: Broad Area ALA 1-hour incubation (DRUG), Broad Area ALA 2 hour incubation (DRUG), broad area ALA 3-hour incubation (DRUG), Spot ALA 2 hour incubation (DRUG), Vehicle PDT (DRUG).

Who is sponsoring clinical trial NCT01475955?

This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01475955's enrollment target sits among peer trials

235 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01524211 · 235 participants · NA

    Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

  • NCT05316155 · 235 participants · Phase 1

    Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  • NCT05353569 · 235 participants · NA

    Coherent Optical Detection of Middle Ear Disease

  • NCT05390918 · 235 participants · NA

    Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01475955, the US trial registry maintained by the National Library of Medicine. NCT01475955 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.